Clinical Roundup Single-cell study provides valuable resource to identify new immunotherapy strategies September 16, 2022Vol.48 No.33
Clinical Roundup Long-term data from AstraZeneca/Merck’s Lynparza shows survival benefit in ovarian cancer September 16, 2022Vol.48 No.33
Clinical Roundup Neoadjuvant Keytruda improves outlook in high-risk melanoma September 16, 2022Vol.48 No.33
Clinical Roundup Immunotherapy before surgery induces complete response in more than half of patients with CSCC September 16, 2022Vol.48 No.33
Clinical Roundup ADAURA trial shows positive results in early-stage NSCLC September 16, 2022Vol.48 No.33
Clinical Roundup GRAIL presents PATHFINDER multi-cancer early detection screening study results September 16, 2022Vol.48 No.33
Clinical Roundup Novartis’ Kisqali provides additional year of survival benefit, including for aggressive HR+/HER2- advanced breast cancer September 16, 2022Vol.48 No.33
Clinical Roundup Zejula shows durable, sustained long-term PFS benefit in first-line platinum-responsive advanced ovarian cancer September 16, 2022Vol.48 No.33
Clinical Roundup Study shows specific sequence of drugs reduces cost of treating metastatic breast cancer while preserving quality of life September 16, 2022Vol.48 No.33
Clinical Roundup Strata Oncology expands Strata PATH trial to eight Sarah Cannon Research Institute sites September 16, 2022Vol.48 No.33
